

PROVIDER QUICK POINTS

PROVIDER INFORMATION



December 8, 2021

Commercial Pharmacy Benefit Exclusion for Nulojix[®] and Susvimo[™]

Effective **January 1, 2022**, the drugs listed in the table below will be excluded from pharmacy benefit coverage due to clinician-administered route of administration and may be available for medical benefit coverage for subscribers who are eligible.

Drug Name
Nulojix [®] (belatacept) IV infusion
Susvimo [™] (ranibizumab) intravitreal injection; intravitreal implant kit

Products Impacted

This applies to commercial lines of business.

Questions?

If you have questions, please contact provider services at **(651) 662-5200** or **1-800-262-0820**.